Clinical

Dataset Information

0

An Open-Label Randomized Phase III Study of Intermittent Oral Capecitabine in Combination with Intravenous Oxaliplatin (Q3W) (“XELOX”) versus Bolus and Continuous Infusion Fluorouracil/Intravenous Leucovorin with Intravenous Oxaliplatin (Q2W) (“FOLFOX4”) as Treatment for Patients with Metastatic Colorectal Cancer who have Received Prior Treatment with CPT- 11 in Combination with 5-FU/LV as First L...


ABSTRACT: Primary objectives: To demonstrate that the combination of capecitabine plus oxaliplatin ("XELOX") is at least equivalent to the combination of 5-fluorouracil plus leucovorin plus oxaliplatin ("FOLFOX-4”) in terms of time to tumor progression or death (TTP) in patients with metastatic colorectal carcinoma who have received prior treatment with CPT-11 in combination with 5-FU as first line therapy. Primary endpoints: At least equivalence with respect time to tumor progression or death (TTP).

PROVIDER: 2515885 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2016-05-25 | GSE81249 | GEO
2016-05-25 | GSE81247 | GEO
2016-05-25 | GSE81237 | GEO
| S-EPMC3871222 | biostudies-literature
| S-EPMC7378659 | biostudies-literature
| S-EPMC6186212 | biostudies-literature